Showing results (31-40 of 49) with videos related to
Sort By:
Pageof 5
Antiviral Therapy|October 1, 2004
Potent antiviral effect of reverset in HIV-1-infected adults following a single oral doseLieven J Stuyver, Tamara R McBrayer, Dirk Schürmann, et al.ERJ Open Research|April 15, 2021
High-dose glucocorticoid treatment of near-fatal bocavirus lung infection results in rapid recoveryMatthias Obenaus, Oliver Schildgen, Dirk Schürmann, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2013
Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patientsHans-Jürgen Stellbrink, Keikawus Arastéh, Dirk Schürmann, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2017
Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)Carey Hwang, Dirk Schürmann, Christian Sobotha, et al.AIDS (London, England)|September 16, 2015
A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individualsDirk Schürmann, Christian Sobotha, Jocelyn Gilmartin, et al.The Journal of Infectious Diseases|August 17, 2012
Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjectsRichard E Nettles, Dirk Schürmann, Li Zhu, et al.International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 19, 2019
Pulmonary nocardiosis in Western Europe-Clinical evaluation of 43 patients and population-based estimates of hospitalization ratesSebastian R Ott, N Meier, Martin Kolditz, et al.The Lancet. HIV|January 9, 2020
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trialDirk Schürmann, Deanne Jackson Rudd, Saijuan Zhang, et al.AIDS Research and Human Retroviruses|September 18, 2024
A Randomized, Double-Blind, Placebo-Controlled, Short-Term Monotherapy Study of MK-6186, an HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor, in Treatment-Naïve HIV-Infected ParticipantsDirk Schürmann, Andreas Hüser, Frieder Pfäfflin, et al.Infection|February 26, 2026
Long-term immune recovery under continuous antiretroviral therapy (ART) among ART-naive people living with HIV in two cohorts in GermanyUwe Koppe, Kirsten Pörtner, Christian Kollan, et al.Pageof 5